Learn details of Women Infertility Pipeline Drugs Review which provides information on the therapeutics under development for Women Infertility and Pharmaceutical Companies involved in therapeutics development for Women Infertility including AbbVie, Bayer AG, Dong-A Socio Holdings Co Ltd , Livzon Pharmaceutical Group Inc , Luye Pharma Group Ltd , Merck & Co Inc and more.
Women Infertility Pipeline Review, H1 2017 provides an overview of the Women Infertility (Women’s Health) pipeline landscape. Infertility is the inability to get pregnant after a year of unprotected intercourse. Pharmaceutical and Healthcare latest pipeline guide on Women Infertility provides comprehensive information on the therapeutics under development for Women Infertility (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase This Single User License PDF Report of 190 pages at: http://www.reportsnreports.com/purchase.aspx?name=944660 .
Pharmaceutical Companies Analyzed includes 4P Therapeutics LLC , AbbVie Inc , Addex Therapeutics Ltd , AlphaMab Co Ltd , APAvadis Biotechnologies Srl , ASKA Pharmaceutical Co Ltd , Astellas Pharma Inc, Bayer AG, Dong-A Socio Holdings Co Ltd , Dongkook Pharmaceutical Co Ltd , ElexoPharm GmbH , EndoCeutics Inc , Enteris BioPharma Inc , Evotec AG , Ferring International Center SA , Forendo Pharma Ltd , Glycotope GmbH , Isifer AB , Kissei Pharmaceutical Co Ltd , Lipicard Technologies Ltd , Livzon Pharmaceutical Group Inc , Luye Pharma Group Ltd , Merck & Co Inc , Navya Biologicals Pvt Ltd, Nippon Shinyaku Co Ltd , Nora Therapeutics Inc , ObsEva SA , Ogeda SA , Orphagen Pharmaceuticals Inc , Pangen Biotech Inc., Pantec Biosolutions AG, PharmaEssentia Corp , Philogen SpA, Repros Therapeutics Inc , Richter Gedeon Nyrt, SK Chemicals Co Ltd , Takeda Pharmaceutical Company Ltd , TocopheRx Inc , ValiRx Plc , Viramal Ltd , Zydus Cadila Healthcare Ltd.
Women Infertility Drug Profile discussed In Report are acolbifene hydrochloride + GnRH Agonist + prasterone , ADX-68692 , AKP-501 , ASP-1707 , barusiban , BAY-1128688 , BAY-1158061 , Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis , Biosimilar 5 for Infertility and Oncology , Biosimilar 6 for Infertility, Oncology and Immunology , Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology , choriogonadotropin alfa biosimilar , choriogonadotropin alfa biosimilar , danazol , Drug 1 for Endometriosis , Drug 2 for Endometriosis , Drug 3 for Endometriosis , Drug 4 for Endometriosis , Drug 5 for Endometriosis , Drug to Antagonize P2X3 for Endometriosis , Drug to Inhibit C-Jun for Endometriosis , Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women’s Health , Drugs for Endometriosis and Uterine Fibroids , EC-313 , elagolix sodium , EVE-104 , FE-999310 , fezolinetant , follicle stimulating hormone biosimilar , follitropin alfa biosimilar , follitropin alfa biosimilar , follitropin alfa biosimilar , follitropin delta , FP-5677 , FSH-GEX , goserelin biosimilar , goserelin ER , Isifera , kisspeptin-54 , KLH-2109 , KN-015 , leuprolide acetate , LM-001 , LM-002 , LT-6121 , menotropins , MIA-602 , MK-8389 , Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility , NAV-013 , NS-580 , NT-100 , OBE-001 , PEG-FSH , Peptide to Agonize FSH Receptor for Women Infertility , Peptides for Endometriosis and Hepatic Tumor , Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor , PGL-1001 , PGL-2001 , progesterone , Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome , relugolix , SKI-2670 , Small Molecule to Antagonize FSH Receptor and LH Receptor for Women’s Health , Small Molecules for Female Infertility 131, Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology 132, Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis 133, Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology 134, Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis 135, Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers 136, Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis 137, SR-16234 138, STI-2833 139, Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology 140, TAK-448 141, telapristone acetate 143, Tetravil 152, TOP-001 154, TOP-002 155, triptorelin 156, triptorelin acetate ER 157, triptorelin biosimilar 158, VAL-201 159, VAL-301 164, vilaprisan 165, VPE-001 166, VPEA-004 167.
Discount is available on Women Infertility report at: http://www.reportsnreports.com/contacts/discount.aspx?name=944660 .
The Women Infertility (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 14, 14, 1, 28, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively. Women Infertility (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women’s Health) and covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
Report also reviews pipeline therapeutics for Women Infertility (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources and features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. Key companies involved in Women Infertility (Women’s Health) therapeutics and all their major and minor projects are discussed in this report. Women Infertility (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
Table of Contents
- List of Tables
- List of Figures
- Global Markets Direct Report Coverage
- Women Infertility Overview
- Women Infertility Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Women Infertility Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Women Infertility Companies Involved in Therapeutics Development
- Women Infertility Dormant Projects
- Women Infertility Discontinued Products
- Women Infertility Product Development Milestones
- Featured News & Press Releases
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441